Transdermal Or Percutaneous Patents (Class 424/449)
  • Patent number: 11318468
    Abstract: A blister assembly comprises at least one collapsible blister adapted, as it is collapsed, to eject a liquid contained therein. The blister assembly comprises a first layer (130) having at least one blister chamber (150) and a second layer (131) sealed to the first layer at least around a periphery of the at least one blister chamber such that a liquid is contained between the first layer and the second layer. The seal between the first and second layers comprises a first planar portion having a first peel strength and a second planar portion having a second peel strength, wherein the first peel strength is greater than the second peel strength, such that when pressure is applied to the blister, the second portion of the seal breaks to release the liquid contained within the chamber into the liquid inlet.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 3, 2022
    Assignee: Binx Health Limited
    Inventor: Tom Edwards
  • Patent number: 11304912
    Abstract: The present application relates to a transdermal therapeutic system comprising a backing layer impermeable to active substances and a polymer matrix on one side of the backing layer impermeable to active substances, wherein the polymer matrix comprises at least one pharmaceutically active substance, at least one inherently non-self-adhesive polymer and at least one plasticizer, said polymer matrix being free of adhesive polymers. The invention further relates to a method of producing the transdermal therapeutic system and to the use thereof as a drug.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 19, 2022
    Inventors: Michael Linn, Markus Müller, Marius Bauer
  • Patent number: 11291730
    Abstract: A composition for treating a wound includes graphene oxide (GO) and hyaluronic acid (HA) that are covalently linked, XAV939, and water. The composition can also include a surfactant, such as PEG. The composition can be topically administered to a subject to treat a wound of the subject. Methods of treating a wound using the composition are also provided.
    Type: Grant
    Filed: October 6, 2018
    Date of Patent: April 5, 2022
    Assignee: ELUCIDERM INC.
    Inventor: Daniel D Holsworth
  • Patent number: 11278549
    Abstract: A method of treating obesity and obesity-related disorders in a mammal is provided. The method comprises the step of administering to the mammal a compound or entity that inhibits the HTR2a receptor.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 22, 2022
    Assignee: McMaster University
    Inventors: Gregory Steinberg, Alex Green
  • Patent number: 11247226
    Abstract: A process capable of commercial scale manufacturing of inexpensive, multilayered shaped film product, without the waste of die-cutting and which products are capable of use independent of a supporting structure on which they are formed, includes placing a first mask over a substrate; delivering a first film-forming composition through the first mask to form a first raw shape on the substrate; removing the first mask; placing a second mask over the first raw shape; delivering a second film-forming composition through the second mask to form a second raw shape on the first raw shape; removing the second mask; and solidifying the first and second raw shapes to provide the shaped film product disposed on the substrate.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: February 15, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Curt Binner, Kenneth A. Pelley
  • Patent number: 11219631
    Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 11, 2022
    Assignee: Vyne Pharmaceuticals Inc.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 11206824
    Abstract: The present invention relates to a gas delivery device comprising a gas releasing molecule and a gas permeable membrane. The invention also relates to the use of the gas delivery device for delivery of gas to an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff and in therapy. The invention further relates to the use of a gas permeable and liquid and solid impermeable membrane to separate a gas releasing molecule and its non-gaseous degradation products from an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: December 28, 2021
    Assignee: Julius-Maximilians-Universitaet Wuerzburg
    Inventors: Lorenz Meinel, Christoph Steiger, Christian Wunder
  • Patent number: 11207297
    Abstract: The present invention relates to liquid pharmaceutical composition suitable for oral administration comprising clonidine or pharmaceutically acceptable salts thereof with at least one buffer and at least one preservative. The present invention also relates to process for preparing the said liquid pharmaceutical composition.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: December 28, 2021
    Assignee: SYRI LTD.
    Inventors: Kamlesh Patel, Sanjaykumar Maganbhai Patel, Viral Mahendrabhai Patel
  • Patent number: 11202764
    Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 21, 2021
    Inventors: Kazuya Kominami, Takito Shima, Naoyuki Uchida, Naoko Fujita, Shigeo Suzuki, Terumitsu Kaiho
  • Patent number: 11198741
    Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: December 14, 2021
    Inventors: Matteo D'Este, Giovanni Gennari
  • Patent number: 11198800
    Abstract: A method of inverting the phase arrangement of the silicone phase and the acrylic phase in a silicone acrylic hybrid composition, the silicone acrylic hybrid composition comprising: a) a silicone acrylic hybrid pressure sensitive adhesive, and b) a solvent, wherein the phase arrangement of the silicone phase and the acrylic phase in the initial silicone acrylic hybrid composition forming a continuous external phase and a discontinuous internal phase is determined by the solvent, comprising the step of adding an activator to the silicone acrylic hybrid composition, wherein the activator a) is liquid at 20° C. and 1013 mbar, b) has a boiling point which is higher than the boiling point of the solvent and/or has a vapor pressure at 20° C.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: December 14, 2021
    Inventor: Marco Emgenbroich
  • Patent number: 11179324
    Abstract: Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: November 23, 2021
    Inventors: Mahmoud Ameri, Michel J. N. Cormier, Scott Sellers, Yuh-Fun Maa
  • Patent number: 11179346
    Abstract: An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 23, 2021
    Inventors: Satoshi Kawakami, Manabu Sogabe
  • Patent number: 11160744
    Abstract: A gel composition containing (a) at least one selected from tocopherol phosphoric acid esters and salts thereof; (b) carrageenan; (c) locust bean gum; (d) at least one selected from agar and glucomannan; and e) water.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 2, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Natsuno Mishina, Naoko Ito, Manami Hatano, Risa Iguchi
  • Patent number: 11160764
    Abstract: The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a patch which shows excellent adhesion to the skin even when drugs and other additives are dissolved into the composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 2, 2021
    Assignees: Medherant Limited, Bostik SA
    Inventors: David Haddleton, David Goubard, Ciaran O'Driscoll
  • Patent number: 11147790
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: October 19, 2021
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Patent number: 11129807
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: September 28, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
  • Patent number: 11090265
    Abstract: The purpose of the present invention is to provide an aqueous preparation for external use, said aqueous preparation comprising an acidic drug such as an arylacetic acid nonsteroidal anti-inflammatory analgesic, having an excellent percutaneous absorbability and giving a good feeling in use. The aqueous preparation for external use comprises the acidic drug or a salt thereof, isostearic acid and an alkanol amine. It is preferred that the aqueous preparation according to the present invention for external use further comprises a C2-6 aliphatic hydroxy acid and has a pH value of 4.5-7.8. The C2-6 aliphatic hydroxy acid is one member or a combination of the same selected from the group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 17, 2021
    Assignee: MEDRX CO., LTD.
    Inventor: Katsuhiro Yamanaka
  • Patent number: 11058651
    Abstract: A topical composition for nociceptive and neuropathic pain relief comprising one or more of menthol, camphor, methyl sulfonyl methane, lidocaine, Arinica montana, harpagophytum tincture, Emu oil, maqui powder, turmeric oil and in some embodiments methyl salicylate or capsaicin with Cannabis sativa.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: July 13, 2021
    Inventor: Bob Fuladi
  • Patent number: 11045483
    Abstract: The subject-matter of the present invention is the use of a therapeutic composition comprising, in an applying carrier, at least one essential oil for relieving muscle and/or joint pain in an animal subject, wherein said composition topically treats an area of the skin of said subject, characterized in that said composition comprises methyl salicylate, which constitutes, with at least one essential oil of the composition containing same in only a small amount or not at all, an active agent within which the rate of transport of the methyl salicylate through the skin is increased by virtue of the oil, which is an essential oil.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 29, 2021
    Assignee: AB7 INNOVATION S.A.S.U.
    Inventor: Rene Chelle
  • Patent number: 11007385
    Abstract: The invention describes methods and agents for inducing in the skin one or more effects selected from stimulating fibroblast migration, stimulating elastin production, reducing expression of inflammatory factors and upregulating specific genes, thereby preventing skin cell aging processes and repairing skin damage. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 18, 2021
    Assignee: REGENICS AS
    Inventors: Runhild Gammelsaeter, Jan Remmereit, Gry Kalstad Lonne, Camilla Margrethe Haglerod
  • Patent number: 10998091
    Abstract: Aspects of the invention include systems for monitoring compliance of a patient with a patch dosage regimen and, where necessary, providing rapid, economical intervention when non-compliance is detected. In some instances, the systems include: a patch comprising an active agent and a patch tag; a reader configured to detect the patch tag; one or more processing devices; and a compliance determination module comprising a computer-readable storage medium comprising instructions that, when executed by the one or more processing devices, determine compliance information from data received from the reader. The compliance information includes data that may be employed to determine whether the patient is complying with the patch dosage regimen. Also provided methods of using the systems, e.g., to monitor patient compliance, as well as components of the systems, e.g., patches, readers, etc.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: May 4, 2021
    Inventor: Sandeep Patil
  • Patent number: 10993910
    Abstract: A biopatch, a bioheater, a biosensor and a bioelectronic patch device are provided. The biopatch comprises a polymer film comprising a biopolymer and a drug loaded in the polymer film. The biopolymer may comprise one or more than one of a bioabsorbable polymer, a biodegradable polymer and a biocompatible polymer. The biopolymer may comprise oxidized starch. The drug may comprise a first drug chemically combined with the oxidized starch and a second drug physically combined with the oxidized starch. The bioheater comprises a heater comprising biometal. The biometal may comprise Mg or Fe. The heater can be controlled wirelessly by an alternating magnetic field.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 4, 2021
    Inventors: Daehyeong Kim, Seunghong Choi, Taeghwan Hyeon, Jongha Lee, Hyerim Cho, Hyunseon Seo
  • Patent number: 10987316
    Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 27, 2021
    Inventors: Jun Liao, Takito Shima, Puchun Liu, Steven Dinh
  • Patent number: 10980753
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: April 20, 2021
    Inventors: Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
  • Patent number: 10963118
    Abstract: An electrode structure and a touch panel including the electrode structure are provided. The electrode structure includes a membrane layer and a metallic nanowires layer having metallic nanowires. A first portion of the metallic nanowires layer is covered by the membrane layer, and a second portion of the metallic nanowires layer is exposed out of the membrane layer. The membrane layer is made of a copolymer formed by mixing two or more materials having different functional groups.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 30, 2021
    Assignee: Cambrios Film Solutions Corporation
    Inventors: Chung-Chin Hsiao, Siou-Cheng Lien, Chia-Yang Tsai, Yi-Wen Chiu, Shu-Ping Hsu
  • Patent number: 10945945
    Abstract: Stabilized skin care compositions are described. The compositions comprise a fish oil component that yields a product of oxidation and the component is stabilized with a radical scavenger, a peroxide decomposer and hydroxylated fatty acid and/or a derivative thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 16, 2021
    Assignee: CONOPCO, INC.
    Inventors: Marina Tomashevskaia, Hasiba Bekto
  • Patent number: 10918686
    Abstract: Disclosed is an oleo gel composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin and Cannabigerol in combination with extract of Olive europaea Fruit Oil, Mentha arvensis leaf oil, and Silica colloidal anhydrous ensuring the delivery of cannabinoids to the deep tissues in order to reduce pain and inflammation of skeletal muscles and joints caused by trauma or/and induced by arthritis/osteoarthritis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 16, 2021
    Assignee: UAB Satimed
    Inventor: Juozas Siurkus
  • Patent number: 10918607
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 16, 2021
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Patent number: 10912734
    Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: February 9, 2021
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh
  • Patent number: 10898489
    Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 26, 2021
    Assignee: Strategic Science & Technologies, LLC
    Inventor: Eric T. Fossel
  • Patent number: 10898503
    Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    Type: Grant
    Filed: January 1, 2016
    Date of Patent: January 26, 2021
    Inventor: Mark Quang Nguyen
  • Patent number: 10888532
    Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base, and a mass per unit area of the adhesive layer is 30 to 90 g/m2.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 12, 2021
    Inventors: Naoko Fujita, Takito Shima, Kazuya Kominami, Naoyuki Uchida
  • Patent number: 10874338
    Abstract: Devices, systems, methods and kits for releasably mounting a medical device on the body or skin of a user are provided. Embodiments include a holder or mounting unit or structure that retains a medical device in a fixed position on a body part of a user or host, such as on the surface of the skin, and/or provides physical and/or electrical coupling to one or more additional components which may be operatively positioned above and/or below the surface of the skin.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 29, 2020
    Inventor: Gary Ashley Stafford
  • Patent number: 10864172
    Abstract: A transdermal patch is provided for use during oil delivery to a user's skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user's skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 15, 2020
    Inventors: Berryinne Decker, Keith Muny, Gary Avalon, Brian Buehner
  • Patent number: 10806914
    Abstract: Disclosed are composite microneedles arrays including microneedles and a film overlaying the microneedles. The film includes a plurality of nano-sized structures fabricated thereon. Devices may be utilized for interacting with a component of the dermal connective tissue. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Devices may be beneficially utilized for delivery of an agent to a cell or tissue. Devices may be utilized to directly or indirectly alter cell behavior through the interaction of a fabricated nanotopography with the plasma membrane of a cell and/or with an extracellular matrix component.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 20, 2020
    Inventor: Russell Frederick Ross
  • Patent number: 10799691
    Abstract: A needle assembly for transdermal administration including a substrate having a first surface and a second surface opposite to the first surface, and fine needles projecting perpendicularly from the first surface. The substrate has grooves on at least one of the first surface and the second surface, and the grooves are formed such that the substrate is deformable following a surface shape of a skin to allow axes of the fine needles to extend in a direction normal to the surface of the skin.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: October 13, 2020
    Inventors: Daizo Uemura, Kazuhiko Shiomitsu
  • Patent number: 10786487
    Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 29, 2020
    Inventors: Mark D. Soll, Joseph K. Rosentel, Jr., James Pate, Natalya Shub, Monica Tejwani-Motwani, Carol Belansky
  • Patent number: 10786574
    Abstract: The present disclosure is directed to transdermal and moisturizing compositions.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 29, 2020
    Inventor: Steven Hoffman
  • Patent number: 10772871
    Abstract: Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: September 15, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
  • Patent number: 10765749
    Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: September 8, 2020
    Inventors: Tatsuya Mori, Naoyuki Saida
  • Patent number: 10758619
    Abstract: Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: September 1, 2020
    Inventors: Susan R. Mallery, Peter E. Larsen, Gary D. Stoner, Steven P. Schwendeman, Kashappa-Goud Desai
  • Patent number: 10758528
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 1, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10751265
    Abstract: A multilayer beauty care product or method is provided. The beauty care product has a water soluble film zone that includes a water soluble film forming polymer and a cosmetic composition with an effective amount of a skin active agent. The product also has a barrier patch having a backing layer and a pressure sensitive adhesive zone. The adhesive zone and the water soluble film zone are continuous, discontinuous, or a combination thereof. The product exhibits a dynamic modulus.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: August 25, 2020
    Assignee: The Procter & Gamble
    Inventors: Emily Charlotte Boswell, Jack Alan Hunter, Michael Joseph Roddy, Elizabeth Anne Wilder
  • Patent number: 10716925
    Abstract: Disclosed is a micro-needle including a tip formed using medicine that penetrates into the skin and melts therein; and at least one guide groove each in a stepped shape inward from the outer surface of the tip, and provided to the tip. The micro-needle configured as above may be used to administer a fixed quantity of medicine within a relatively short period of time. Also, since a guide space stepped based on the tip is provided to a base that supports the tip, a large amount of medicine may easily penetrate into the skin.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: July 21, 2020
    Assignee: QuadMedicine
    Inventor: Sun Young Baek
  • Patent number: 10717904
    Abstract: An adhesive preparation containing bisoprolol includes a backing and a pressure-sensitive adhesive layer formed on one side of the backing. The pressure-sensitive adhesive layer contains a polymer prepared through copolymerization of monomer components including a hydroxyl group-containing monomer and an alkyl (meth)acrylate monomer (component (A)), a polymer prepared through copolymerization of monomer components including a methyl methacrylate monomer and a butyl methacrylate monomer (component (B)), and bisoprolol (component (C)).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 21, 2020
    Assignee: TOA EIYO LTD.
    Inventors: Eriko Abe, Yu Tachikawa, Satoshi Ameyama, Naoko Urushihara, Jun Ishikura, Tetsuya Nakamura, Akira Yokouchi, Yoshitaka Inoue, Kazuhiro Aoyagi, Tomoya Tanaka, Naohiro Nishida, Kunihiro Minami
  • Patent number: 10702469
    Abstract: A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: July 7, 2020
    Inventor: Ketan R. Patel
  • Patent number: 10688159
    Abstract: A treatment for pruritus is described that is based upon amylase. The amylases (?-, ?-, ?-amylase) are noted for the cleavage of the ?-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that ?-amylase is effective in the reduction of pruritus (itching) of affected tissue.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 23, 2020
    Inventors: Joseph Charles Salamone, Ann Beal Salamone, Kelly Xiaoyu Chen Leung, Katelyn Elizabeth Reilly
  • Patent number: 10675254
    Abstract: Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis. Packaged iontophoretic systems, kits including iontophoretic devices, and methods of making iontophoretic devices are also provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 9, 2020
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Adchara Pongpeerapat
  • Patent number: 10660962
    Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 26, 2020
    Assignee: CMPD Licensing, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge